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Abstract 
Endothelin-mediated vasoconstriction may theoretically aggravate ischemic neuronal damage. Although investigators have dem- 
onstrated that endothelins are produced by cerebral microvessel endothelial cells, astrocytes and neurons in vitro, whether endothe- 
lins are produced during cerebral ischemia is still unclear. The purpose of this study, therefore, was to measure endothelin-1 in brain 
tissue and plasma following middle cerebral artery occlusion and to examine the relationship between brain tissue and plasma 
endothelin-1 levels. The middle cerebral artery of rabbits was occluded for 2, 4 or 24 h. The amount of endothelin-1 in both brain 
tissue and plasma was determined by RIA. The results demonstrate that the concentrations of endothelin-1 in the ischemic brain 
tissue and plasma are both significantly increased after focal cerebral ischemia (P < 0.01). The data confirm that an acute and marked 
increase of endothelin-1 in brain tissue and plasma is associated with focal ischemic events. The possibility that endothelin-1 has 
a role in neuronal cell damage following focal ischemia warrants further attention. 
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Endothelins (ET), a group of vasoconstrictor peptides, 
were isolated from the supernatant of cultured endothe- 
lial cells [22]. Endothelin-1 (ET-1) is found in the CNS 
[19,20] and is produced by endothelial cells, astrocytes 
and neurons [6,9,23]. There are specific, high-affinity and 
high-density binding sites for ET-1 in nearly all regions 
of the brain [7,19]. ET-1 causes vasospasm in cerebral 
vessels and reduces cerebral blood flow (CBF) when ad- 
ministered into the cisterna magna, neostriatum and 
brain parenchyma [12] or when topically applied to ex- 
posed brain vessels [13]. ET-1 may not only act as a 
vasoconstrictor in the brain but may also modulate glial 
cell growth and mitosis [10], neurosecretion, such as go- 
nadotropin secretion [18], and cerebral glucose metabo- 
lism [4]. Recently, several reports have confirmed the 
increased ET concentrations in plasma and cerebrospi- 
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nal fluid (CSF) in subarachnoid hemorrhage and acute 
cerebral infarction but decreased CSF ET concentrations 
in patients with Alzheimer's disease [8,24,25]. Following 
transient forebrain ischemia in stroke-prone spontane- 
ously hypertensive rats, Yamashita et al. demonstrated 
an increased production of  ET in the hippocampus [21]. 
However, it is unknown whether ET-1 is released follow- 
ing focal cerebral ischemia, how early ET-1 is released 
and from where the ET-1 originates? 
In this study, we measured the level of  ET-1 in both 
brain tissue and plasma following middle cerebral artery 
occlusion (MCAO) in rabbits to determine if the release 
of  ET-1 is related to focal cerebral ischemia, to examine 
the relationship of ET-1 release between brain tissue and 
plasma as well as the possible mechanism of ET-1 in- 
crease during focal cerebral ischemia. 
Twenty-four New Zealand white male rabbits (2.5-3.0 
kg) were anesthetized with sodium pentobarbital (30 mg/ 
kg i.v.). A femoral artery was catheterized to monitor 
arterial blood pressure and to obtain blood for analysis 
of blood gases, blood pH and blood glucose. Blood gases 
were analyzed once during the operation. Animals were 
48 L.-G. Bian et al./Neuroscience Letters 174 (1994) 47 50 
given a 30% OJ70% NO 2 gas mixture to maintain a P a O 2  
level of -> 90 mmHg. Body temperature was measured 
with a rectal probe and maintained at 37-37.5°C with a 
heating pad. The MCAO was performed according to 
the method described by O'Brien et al. with a minor 
modification [17]. The middle cerebral artery was ex- 
posed at its origin, a small wire hook was inserted under 
the MCA and then the MCA was coagulated and cut at 
its origin. Four groups of rabbits (six rabbits in each) 
were euthanized by decapitation at 0, 2, 4 and 24 h fol- 
lowing MCAO. The brains were quickly removed and 
a 5-mm-thick coronal slice centered around the middle 
cerebral artery was cut. Tissue samples were obtained 
from both hemispheres (ipsilateral and contralateral to 
the occlusion) and stored at -20°C for ET-1 measure- 
ments. 
Plasma ET-1 levels were measured in all groups of 
rabbits. Blood was drawn at 0, 2, 4 and 24 h following 
MCAO and transferred to a chilled polypropylene tube 
containing 500 U/ml aprotinin (Sigma) and 1 mg/ml 
EDTA. The samples were centrifuged at 3000 rpm for 
15 min at 4°C and then stored at -70°C until assayed. 
Brain tissue was homogenized in 10 vols. of 0.1 N acetic 
acid and centrifuged at 3500 rpm for 20 min at 4°C. The 
supernatants were purified immediately using C ~8 Sep- 
Pak cartridges (Millipore). Each cartridge was washed 
with 15 ml 4% acetic acid and the endothelin fractions 
were then eluted with 2.5 ml 60% acetonitrile in 0.5% 
ammonium acetate. The samples were dried by evapora- 
tion in a speedVac apparatus (Savant, Farmingdale, 
NY). The dried fractions were reconstituted with 0.25 ml 
of the RIA buffer. ET-1 was measured using a competi- 
tive RIA kit (RIK-6901; Peninsula Lab, Belmont, CA). 
Duplicate samples of 0.1 ml were assayed according to 
the manufacturer's instructions. The ET-1 assay has a 
<10% cross-reactivity with ET-2 and ET-3 and does not 
cross-react with a variety of other hormones. For each 
sample assay, all procedures were performed with the 
tubes and reagents in an ice bath. The level of plasma 
ET-1 was expressed as ET-1 pg/ml plasma and the level 
of brain tissue ET-1 was expressed as ET-1 pg/mg pro- 
tein. 
All physiological parameters were in the normal 
range. There were no significant differences between con- 
trol and MCAO groups in terms of the mean arterial 
blood pressure, blood gases (PaO> P a C O 2  and PaHCO3), 
blood pH and blood glucose. 
Fig. 1 shows the changes of ET-1 in the brain samples. 
In the contralateral hemisphere the ET-1 concentration 
was similar in all groups. In the ischemic hemisphere, 
however, the ET-1 concentration was significantly ele- 
vated from a value of 4.67 + 0.28 pg/mg protein in the 
control group to 5.67 + 0.59 and 7.57 + 0.91 pg/mg pro- 
tein in ischemic hemisphere following 2 and 4 h of 
MCAO (P < 0.01) respectively. By 24 h of MCAO, the 
ET-1 concentration in the ischemic hemisphere had ele- 
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Fig. 1. Changes of ET-1 content in ipsilateral hemisphere (o) and 
contralateral hemisphere (o) in rabbits. ET-1 content was measured in 
groups of six rabbits immediately (0 time) and at intervals up to 24 h 
following MCAO.  Values shown are mean + S.E.M. of differences be- 
tween values at control and those at subsequent times. *P < 0.05, 
**P < 0.01 vs. control group. 
Fig. 2. Changes of ET-1 content in brain tissue (m) and plasma (n) in 
rabbits. ET-1 content was measured in groups of  six rats immediately 
(0 time) and at intervals up to 24 h following MCAO.  Values shown 
are mean + S.E.M. of  differences between values at 0 time and those 
at subsequent times. *P < 0.01, **P < 0.00l vs. control group. 
vated to 16.91 + 3.67 pg/mg protein which was four-fold 
higher than in the control group. 
The changes of plasma ET-1 concentration is shown 
in Fig. 2. In the control group the plasma ET-1 content 
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was 27.57 + 2.28 pg/ml. Following 2 h of MCAO, it 
increased to 48.25 + 4.49 pg/ml (175% of control). The 
plasma ET-1 level increased in a time-dependent fashion 
reaching to 62.49 + 4.43 pg/ml at 4 h and 73.75 + 5.83 
pg/ml at 24 h following MCAO. 
In the present study we have demonstrated an increase 
of ET-1 level both in the ischemic area and plasma fol- 
lowing MCAO in rabbits. In the first 4 h of MCAO, 
ET-1 levels were increased in the ipsilateral hemisphere 
but the amount was not high. By 24 h of MCAO, how- 
ever, the level of ET-1 increased dramatically in the ipsi- 
lateral hemisphere and was four-fold higher than in the 
control hemisphere. Our studies have also demonstrated 
that the plasma ET-1 level is increased gradually after 
MCAO in rabbits. 
The source of the ET-1 in the ischemic hemisphere is 
uncertain. It is not present in the blood stream as similar 
concentrations are not found in the non-ischemic hemi- 
sphere. The increased tissue ET-1 is also not likely to 
have come from the blood stream. The concentrations 
reached after 24 h of MCAO, 17 pg/mg protein, cor- 
responds to a concentration of ~2 ng/ml brain water 
(assuming 1 mg brain protein to 7.5 mg brain water), 
30-fold higher than the plasma concentration found at 
a similar time point. So, even though the blood-brain 
barrier may have been disrupted after 24 h of MCAO 
[15] and present ET that can penetrate through the CNS 
[11], an influx of plasma ET-1 is unlikely to be the cause 
of the higher tissue ET-1 in the ischemic hemisphere. 
The two other potential sites of ET-1 production in the 
ischemic hemisphere are the brain vascular endothelium 
and the brain parenchyma. Endothelin was first discov- 
ered being produced by cultured endothelial cells [22] but 
Takahashi et al. have demonstrated that the presence of 
immunoreactive ET (irET), ET mRNA and ET receptors 
in the brain tissue, although the distributions of irET, ET 
mRNA and ET receptors were different in the brain 
regions [19]. Following cerebral ischemia, brain vascular 
endothelial cells may be injured, thus synthesis of ET-1 
could increase in these regions [5]. 
The cause of the ischemia induced increase in plasma 
ET-1 found here and also seen by other authors is still 
unclear [25]. However, it may be a secondary response 
to the increase in brain ET-1 [16]. Suprapharmacological 
doses of ET-1 have been ascribed neuromodulator and 
paracrine functions [3,12]. It causes a systemic sympa- 
thoadrenal activation, including a rise in plasma cat- 
echolamine and vasopressin level [14], that might stimu- 
late peripheral organs to release ET into the circulation. 
A number of studies have examined whether ET-1 
might play a role in ischemic brain injury. Injection of 
high doses of ET-I (43-430 pmol/rat) into the caudate 
putamen has produced local brain ischemia in rats [1,2] 
which may be due to a reduction in local CBF [13]. The 
concentrations used in those experiments (-20-200 pg/g 
wet weight if the endothelin distributes within the whole 
brain) are two to three orders of magnitude higher than 
the tissue concentrations found in the ischemic tissue in 
this study. However, if the ET-1 is generated by the 
vascular endothelium, it is possible that local concentra- 
tions of ET-1 may be much higher than found in the 
whole ischemic tissue and they might be high enough to 
decrease CSF and perhaps potentiate the ischemic brain 
injury. ET could produce a locally deregulated metabolic 
state by reducing CBF while stimulating tissue metabo- 
lism simultaneously in the same region. This condition 
may aggravate the ischemic injury [4]. Also as noted 
above, smaller amounts of ET injected intraventricularly 
may have an effect on systemic parameters including the 
release of vasoconstrictors and activators of the sympa- 
thetic nervous system. In the ipsilateral hemisphere, a 
local increase of ET-1 may be an important factor in the 
pathogenesis and outcome of cerebral ischemia which 
may be due to the release of excitotoxic amino acids, and 
increased glial and neuronal intracellular calcium. 
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